VWF
von Willebrand factor
As of the edition of 20 October 2026, VWF (von Willebrand factor, UniProt P04275) has 3 drugs tested at it and 4 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P04275
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 48
- Disease areas
- Blood and lymph; Heart and blood vessels; Inherited and neonatal; Mental health
- Registered trials of its drugs
- 17
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Caplacizumab | Marketed | Phase 3 | Ends 2031 |
| Egaptivon pegol | Stopped | Phase 2 | none listed |
| Cinaxadamtase alfa | Marketed | No phase stated | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Undetermined | 2 |
| Total on the list | 4 |
The other 2 companies at VWF
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at VWF, ranked, with the facts behind eachRequest access. Nothing is shown until you do.